Life sciences company Azenta (NASDAQ:AZTA) reported calendar Q3 2026 [fiscal Q4 2026] results beating Wall Street’s revenue expectations, with sales up 5.1% year on year to $167.1 million. Its non-GAAP profit of $0.28 per share was significantly above analysts’ consensus estimates.

Is now the time to buy Azenta? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Azenta’s third quarter results were well received by the market, reflecting stronger-than-expected sales and notable improvement in profitability. Management attributed the outperformance to sustained growth in Sample Repository Services and Consumables and Instruments, as well as an operational turnaround in key sequencing and gene synthesis businesses. Interim CEO Dr. Martin Madaus highlighted improved booking trends and more focused commercial execution, stating, “Expanded commercial coverage and a stronger operating focus have contributed to better execution of our opportunities.” The quarter also benefited from restructuring actions that increased efficiency and supported share repurchases.

Looking ahead, Azenta’s guidance relies on scaling its recurring revenue streams, integrating newly acquired gene synthesis technologies, and further optimizing its cost structure. Management believes that the commercialization of Elegen and SynPlexity platforms, along with continued investment in digital and product initiatives, will underpin organic growth. CFO Lawrence Lin commented, “Our outlook incorporates those benefits, as well as the investments required to integrate and commercialize the new Multiomics capabilities.” While legacy Sanger sequencing remains a headwind, the company expects improvements in margin and cash generation as restructuring benefits accrue throughout the year.

Key insights from management’s remarks

Management credited third quarter momentum to recurring revenue growth, operational improvements, and the initial impact of new product strategies, while also addressing challenges in the Automated Stores and Sanger sequencing segments.

• Recurring revenue strength: Sustained double-digit growth in Sample Repository Services and Consumables and Instruments was central to performance, as these segments offer steady, high-margin streams less vulnerable to market fluctuations.
• Operational turnaround in Multiomics: The Multiomics segment, which includes GENEWIZ, showed booking improvements and early results from refocusing on high-growth sequencing and gene synthesis services, offsetting the ongoing decline in Sanger sequencing.
• Automated Stores challenges and quality improvements: Automated Stores continued to face headwinds due to constrained customer capital spending and past quality issues, but management noted recent improvements in product quality and booking trends, alongside plans for new product launches in 2027.
• Restructuring and cost control: Organizational restructuring within Multiomics and streamlining of U.S. lab operations are expected to generate $11 million in annualized savings, with cost actions helping to preserve margins despite lower volumes in some parts of the business.
• New technology integration: The acquisitions of SynPlexity and the exclusive license from Elegen are intended to expand Azenta’s footprint in AI-enabled drug discovery workflows, enabling higher-throughput, cost-competitive gene synthesis, and positioning GENEWIZ for further growth in the U.S. and globally.

Drivers of future performance

Azenta’s outlook is driven by commercialization of new gene synthesis technologies, expanded recurring revenue, and disciplined cost management, while navigating persistent headwinds in legacy segments.

• Commercialization of gene synthesis platforms: Management expects the integration and global rollout of Elegen’s and SynPlexity’s proprietary DNA synthesis technologies to support growth in high-value genomic discovery, particularly in AI-enabled drug development. Early feedback from customers has been positive, though the ramp-up period is expected to last through next year.
• Recurring revenue and product expansion: Growth in Sample Repository Services and Consumables and Instruments remains a priority, with new product launches—such as ultra-low temperature and modular Automated Stores—aimed at standardizing offerings and addressing evolving customer needs. Management anticipates these will bolster the revenue base over time.
• Margin expansion and restructuring benefits: Azenta forecasts adjusted EBITDA margin improvement of 200-250 basis points, driven by gross margin gains, operating leverage, and the benefits of ongoing restructuring and automation. However, integration costs and continued decline in Sanger sequencing will partially offset these gains in the near term.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will monitor (1) the pace of integration and commercial adoption of SynPlexity and Elegen technologies, (2) execution of restructuring efforts and realization of targeted margin improvements, and (3) sustained momentum in recurring revenue businesses and new product rollouts, particularly in Automated Stores. Progress in these areas will be important indicators of Azenta’s ability to deliver on its growth and profitability commitments.

Azenta currently trades at $48.06, up from $40.48 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

High quality stocks for all market conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week, free. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.